INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.265
-0.055 (-4.17%)
At close: Mar 5, 2026, 4:00 PM EST
1.290
+0.025 (1.99%)
After-hours: Mar 5, 2026, 7:52 PM EST
INmune Bio Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for INmune Bio stock have an average target of 4.30, with a low estimate of 0.60 and a high estimate of 8.00. The average target predicts an increase of 239.92% from the current stock price of 1.27.
Analyst Consensus: Hold
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $8 | Strong Buy | Maintains | $30 → $8 | +532.41% | Jul 2, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 1, 2025 |
| Scotiabank | Scotiabank | Buy → Sell Downgrades $23 → $0.6 | Buy → Sell | Downgrades | $23 → $0.6 | -52.57% | Jul 1, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +2,271.54% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +1,718.18% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
51.00K
from 14.00K
Increased by 264.29%
Revenue Next Year
n/a
from 51.00K
EPS This Year
-1.96
from -2.11
EPS Next Year
-0.94
from -1.96
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 52,500 | n/a | ||||
| Avg | 51,000 | n/a | ||||
| Low | 49,000 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 275.0% | - | ||||
| Avg | 264.3% | - | ||||
| Low | 250.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.02 | -0.76 | ||||
| Avg | -1.96 | -0.94 | ||||
| Low | -1.88 | -1.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.